- Research News
- August 29, 2017
Next-generation drug testing on chips
Improvements to tiny body-on-a-chip devices could lead to next-generation pre-clinical testing of drug toxicity
Researchers at Kyoto University’s Institute for Integrated Cell-Material Sciences (iCeMS) in Japan have designed a small ‘body-on-a-chip’ device that can test the side effects of drugs on human cells. The device solves some issues with current, similar microfluidic devices and offers promise for the next generation of pre-clinical drug tests.
The Integrated Heart/Cancer on a Chip (iHCC) was used to test the toxicity of the anti-cancer drug doxorubicin on heart cells. The researchers, led by iCeMS’s Ken-ichiro Kamei, found that, while the drug itself was not toxic to heart cells, a metabolite of the drug resulting from its interaction with cancer cells was.
Further details are available at the following page:
Kyoto University: Next-generation drug testing on chips
Capturing the surprising flexibility of crystal surfaces
December 4, 2018
Essential modifications for healthy brain function
November 9, 2018
Mechano-sensing and resistance during development of the fruitfly wing
September 10, 2018